



NEXT STEPS: ACT-A Prioritized Strategy & Budget for 2021

Member States COVID-19 Briefing

18 FEBRUARY 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis





The ACT-Accelerator is evolving in a rapidly changing world....

...the new strategy for 2021 reflects these changes

CONTEXT: ACT-Accelerator has helped lay the **groundwork for 3 robust lines of defense** against COVID-19 globally in 2021



Vaccines: with COVAX Facility & products COVID infection can be prevented everywhere
(+2 Bn doses for 190 countries)



Tests: with new, affordable high-quality rapid tests, COVID can be detected anywhere
(900 m tests for LICs/LMICs)



Treatment: with repurposed drugs, life-saving treatments can be delivered anywhere
(dexta stockpile for LICs/LMICs)



Equitable Access: crucial investments to ensure access & stimulate update, everywhere




Global Access & Allocation Framework & COVAX Mechanisms



Catalytic health systems support to deliver new products & PPE

Many generous supporters are contributing to ACT Accelerator success

A broad coalition of public (70%), private (12%) & multilateral donors



ACT-A contributions – in % of total commitments¹, as of 3 February 2021

US\$ 4 billion additional for vaccine procurement & delivery is being finalized with the United States


Note: all financial commitments can be accessed at <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>.

1. US\$ 6 billion include \$470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs


2. Excluding US\$ 267m by donors to the Global Fund COVID-19 Response Mechanism and redistributed to ACT-A pillars 3. Contributions <US\$ 20m

Today: an evolving pandemic with an evolving virus

110 million cases & >2 million deaths



Variants of Concern in at least 100 countries



Under investment in global solutions & increasing bilateral action


ACT-Accelerator has 4 Strategic Priorities for 2021



Rapidly scale-up **delivery of >2 B doses of vaccine** through COVAX



Bolster R&D, eval & regulatory pathways, to **optimize products & address variants**



Ensuring 3 robust lines of defense against the virus & variants, everywhere



Stimulate **rapid & effective uptake of tests, therapeutics & PPE**




Ensure **robust pipeline** of essential tests, therapeutics & PPE in LMICs

US\$27.2 Bn is needed for ACT-A Strategic Priorities in 2021

1 Rapidly scale-up **delivery** of >2 B doses of vaccine

2 Bolster R&D & regulatory paths to **optimize products & address variants**


3 Stimulate rapid **uptake of tests, treatments & PPE** in LIC/LMICs



4 Ensure robust **supply pipeline** of essential tests, treatments & PPE for LICs/LMICs

Updates to the draft Strategy based on feedback so far


Detailed Deliverables by agency




Fully aligned with WHO SPRP



Budget view by Priority & by Pillar




Recognized donors prominently




Strengthened narrative



Reflected wider needs beyond ACT-A




Next Steps to finalize the ACT-A Strategy & Budget 2021:




Access here: <https://www.who.int/publications/m/item/act-a-prioritized-strategy-and-budget-for-2021>

Feedback here: ACTAccelerator@who.int



Annex

The ACT-Accelerator has built a detailed view of its agency-specific deliverables & funding needs for 2021



ACT-A funding gap by Pillar & Strategic Priority, 2021

Last update: 29 Jan 2021

by Pillar

USD\$ billions

	Q1/Q2 2021	Q3/Q4 2021	Total 2021
Diagnostics	1.9	7.0	8.9
Therapeutics	1.4	1.8	3.2
Vaccines	7.8	<0.1	7.8
Health Systems Connector	3.2	4.3	7.4
Total	14.2	13.1	27.2

by Strategic Priority

USD\$ billions

	Q1/Q2 2021	Q3/Q4 2021	Total 2021
1. Rapidly scale delivery of 2 billion vaccines doses through COVAX	6.4	<0.1	6.4
2. Bolster R&D, product evaluation & regulatory pathways	1.6	0.2	1.8
3. Stimulate rapid & effective uptake of diagnostics (Dx), therapeutics (Tx) & PPE in LMICs	2.0	3.8	5.8
4. Ensure robust supply pipeline of essential Dx, Tx & PPE for LMICs	4.2	9.0	13.2
Total	14.2	13.1	27.2

Note: numbers are rounded to closest figure

4th Facilitation Council¹ highlights (held, 9 Feb)

- **Common challenges recognized: variants, equitable access to tools & vaccines supply**
- **Urgency to move from Principle to execution of the Strategy**
- **Broad political support**

Livestreamed: 1488 views

The screenshot shows three news snippets. The first is from swissinfo.ch titled 'U.S., changing course, joins WHO programme aimed at ...'. The second is from Times of India titled 'US to become participant in COVAX high-level council'. The third is from News24 titled 'US to participate in WHO meetings on boosting global pandemic cooperation'.

Call for pharma action

The screenshot shows a World Economic Forum article titled '4 principles for urgent pharma action to combat COVID-19'. The article is dated 09 Feb 2021 and is authored by Dag-Inge Ulstein and John-Arne Rutten. It includes a photo of a person receiving a vaccine. The article lists four principles for urgent pharmaceutical action to combat COVID-19.

<https://www.weforum.org/agenda/2021/02/4-principles-pharma-action-combat-covid19/>

Co-Chair Outcome statement

The statement, titled 'Statement of the Co-Chairs on the 4th ACT Accelerator Facilitation Council, 9 February 2021', discusses the global pandemic's impact and the need for a swifter global response. It details the progress of the ACT Accelerator, including funding secured, COVAX's progress, and the development of new diagnostic tests and pharmaceuticals.

<https://www.who.int/publications/m/item/statement-of-the-co-chairs-of-the-4th-act-accelerator-facilitation-council>

¹ <https://www.who.int/publications/m/item/act-accelerator-facilitation-council---terms-of-reference>